These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1101 related articles for article (PubMed ID: 29301958)

  • 21. Cytokine-like molecule CCDC134 contributes to CD8⁺ T-cell effector functions in cancer immunotherapy.
    Huang J; Xiao L; Gong X; Shao W; Yin Y; Liao Q; Meng Y; Zhang Y; Ma D; Qiu X
    Cancer Res; 2014 Oct; 74(20):5734-45. PubMed ID: 25125657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.
    Jazirehi AR; Baritaki S; Koya RC; Bonavida B; Economou JS
    Cancer Res; 2011 Feb; 71(4):1406-17. PubMed ID: 21159666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma.
    Carcamo S; Nguyen CB; Grossi E; Filipescu D; Alpsoy A; Dhiman A; Sun D; Narang S; Imig J; Martin TC; Parsons R; Aifantis I; Tsirigos A; Aguirre-Ghiso JA; Dykhuizen EC; Hasson D; Bernstein E
    Cell Rep; 2022 Apr; 39(1):110637. PubMed ID: 35385731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
    Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
    Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting
    Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
    Front Immunol; 2021; 12():738958. PubMed ID: 34721405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.
    Ma HL; Whitters MJ; Konz RF; Senices M; Young DA; Grusby MJ; Collins M; Dunussi-Joannopoulos K
    J Immunol; 2003 Jul; 171(2):608-15. PubMed ID: 12847225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
    Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes.
    de Castro RO; Previato L; Goitea V; Felberg A; Guiraldelli MF; Filiberti A; Pezza RJ
    J Biol Chem; 2017 May; 292(20):8459-8471. PubMed ID: 28381560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
    PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
    Winter H; Hu HM; Urba WJ; Fox BA
    J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PBAF chromatin remodeler complexes that mediate meiotic transitions in mouse.
    de Castro RO; Previato de Almeida L; Carbajal A; Gryniuk I; Pezza RJ
    Development; 2022 Sep; 149(18):. PubMed ID: 36111709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8
    Ji Y; Fioravanti J; Zhu W; Wang H; Wu T; Hu J; Lacey NE; Gautam S; Le Gall JB; Yang X; Hocker JD; Escobar TM; He S; Dell'Orso S; Hawk NV; Kapoor V; Telford WG; Di Croce L; Muljo SA; Zhang Y; Sartorelli V; Gattinoni L
    Nat Commun; 2019 May; 10(1):2157. PubMed ID: 31089138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
    Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
    J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer.
    Yamashita N; Morimoto Y; Fushimi A; Ahmad R; Bhattacharya A; Daimon T; Haratake N; Inoue Y; Ishikawa S; Yamamoto M; Hata T; Akiyoshi S; Hu Q; Liu T; Withers H; Liu S; Shapiro GI; Yoshizumi T; Long MD; Kufe D
    Mol Cancer Res; 2023 Mar; 21(3):274-289. PubMed ID: 36445328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
    Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
    J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
    Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
    Hou J; Wang Y; Shi L; Chen Y; Xu C; Saeedi A; Pan K; Bohat R; Egan NA; McKenzie JA; Mbofung RM; Williams LJ; Yang Z; Sun M; Liang X; Rodon Ahnert J; Varadarajan N; Yee C; Chen Y; Hwu P; Peng W
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rα
    Kim SH; Cho E; Kim YI; Han C; Choi BK; Kwon BS
    Nat Commun; 2021 Sep; 12(1):5314. PubMed ID: 34493727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.